EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease Using Functional Respiratory Imaging: An In Silico Study

Omar S Usmani, Benjamin Mignot, Irvin Kendall, Roberta De Maria, Daniela Cocconi, George Georges, Nicola Scichilone

Journal of Aerosol Medicine and Pulmonary Drug Delivery · 01.06.2021 · 34 (3) · 204-211

DOI: 10.1089/jamp.2020.1601 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Aerosol Medicine and Pulmonary Drug Delivery, online erschienen am 14.06.2021. Verfasst von Omar S Usmani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Airway Disease Section, National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London, United Kingdom. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Functional respiratory imaging (FRI) is a computational fluid dynamics-based technique using three-dimensional models of human lungs and formulation profiles to simulate aerosol deposition.

Methods

FRI was used to evaluate lung deposition of extrafine beclomethasone dipropionate (BDP)/formoterol fumarate (FF)/glycopyrronium bromide (GB) and extrafine BDP/FF delivered through pressurized metered dose inhalers and to compare results with reference gamma scintigraphy data. FRI combined high-resolution computed tomography scans of 20 patients with moderate-to-severe chronic obstructive pulmonary disease (mean forced expiratory volume in 1 second 42% predicted) with in silico computational flow simulations, and incorporated drug delivery parameters to calculate aerosol airway deposition. Inhalation was simulated using profiles obtained from real-life measurements.

Results

Total lung deposition (proportion deposited in intrathoracic region) was similarly high for both products, with mean ± standard deviation (SD) values of 31.0% ± 5.7% and 28.1% ± 5.2% (relative to nominal dose) for BDP/FF/GB and BDP/FF, respectively. Pairwise comparison of the deposition of BDP and FF gave a mean intrathoracic BDP/FF/GB:BDP/FF deposition ratio of 1.10 ( p = 0.0405). Mean intrathoracic, central and peripheral deposition ratios for BDP were 1.09 (95% confidence interval [CI]: 1.05–1.14), 0.92 (95% CI: 0.89–0.96), and 1.20 (95% CI: 1.15–1.26), respectively, and for FF were 1.11 (95% CI: 1.07–1.15), 0.94 (95% CI: 0.91–0.98), and 1.21 (95% CI: 1.15–1.27), within the bioequivalence range (0.80–1.25) for intrathoracic and central regions, and slightly exceeding the upper boundary in the peripheral region. Mean ± SD central:peripheral deposition (C:P) was 0.48 ± 0.13 for BDP/FF/GB and 0.62 ± 0.17 for BDP/FF, indicating a higher proportion of drug deposition in the small airways than in the large airways.

Conclusion

FRI demonstrated similar deposition patterns for extrafine BDP/FF/GB and BDP/FF, with both having a high lung deposition. Moreover, the deposition patterns of BDP and FF were similar in both products. Furthermore, the C:P ratios of both products indicated a high peripheral deposition, supporting small airway targeting and delivery of these two extrafine fixed combinations, with a small difference in ratios potentially due to mass median aerodynamic diameters.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveAdministration, InhalationAdrenal Cortex HormonesBeclomethasoneComputer SimulationDrug CombinationsFormoterol FumarateHumansLungTreatment Outcome

Stichwörter der Autor:innen

combination drugextrafinefunctional respiratory imaginginhaled corticosteroidlung depositionpressurized metered-dose inhaler

Substanzen

Adrenal Cortex HormonesDrug CombinationsBeclomethasoneFormoterol Fumarate

Autor:innen und Institutionen

  • Airway Disease Section, National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London, United Kingdom.
  • FluidDA nv, Kontich, Belgium.
  • Chemistry Manufacturing and Controls, Chiesi Farmaceutici SpA, Parma, Italy.
  • Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
  • Division of Respiratory Diseases, Department of Promoting Health, Maternal-Infant Excellence and Internal and Specialized Medicine (Promise), G. D'Alessandro, University of Palermo, Palermo, Italy.

Zitieren

APA

Usmani, O. S., Mignot, B., Kendall, I., Maria, R., Cocconi, D., Georges, G., & Scichilone, N. (2021). Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease Using Functional Respiratory Imaging: An In Silico Study. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 34(3), 204-211. https://doi.org/10.1089/jamp.2020.1601

Vancouver

Usmani OS, Mignot B, Kendall I, Maria R, Cocconi D, Georges G, et al. Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease Using Functional Respiratory Imaging: An In Silico Study. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2021;34(3):204-211. doi:10.1089/jamp.2020.1601

BibTeX
@article{Usmani2021,
  author = {Usmani, Omar S and Mignot, Benjamin and Kendall, Irvin and Maria, Roberta De and Cocconi, Daniela and Georges, George and Scichilone, Nicola},
  title = {Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease Using Functional Respiratory Imaging: An In Silico Study},
  journal = {Journal of Aerosol Medicine and Pulmonary Drug Delivery},
  year = {2021},
  volume = {34},
  number = {3},
  pages = {204--211},
  doi = {10.1089/jamp.2020.1601}
}
Kostenlos starten →